Mumps: Comprehensive Disease Research Report

1. Disease Information

Overview. Mumps is an acute, vaccine-preventable systemic viral infection caused by mumps virus (MuV), a member of genus Orthorubulavirus (family Paramyxoviridae), classically presenting with fever, headache, myalgia, and the hallmark finding of painful, non-suppurative swelling of one or both parotid salivary glands (parotitis), though up to a third of infections are subclinical or present only with nonspecific respiratory symptoms. Historically a universal childhood infection, mumps is now primarily controlled through the combined measles-mumps-rubella (MMR) vaccine, but it remains one of the more vaccine-mismatch-prone and outbreak-prone of the "eliminated" childhood diseases, with recurring resurgences in highly vaccinated populations (college students, military recruits, close-contact settings) attributed to a combination of waning immunity and genotype mismatch between vaccine and circulating strains (PMC7048016; PMC12711706).

Key identifiers: - ICD-11: 1D80 Mumps — ICD-11 MMS - ICD-10-CM: B26 (Mumps), with subcodes B26.0 (mumps orchitis), B26.1 (mumps meningitis), B26.2 (mumps encephalitis), B26.3 (mumps pancreatitis), B26.8 (mumps with other complications), B26.9 (mumps without complication) - MeSH: D009107 (Mumps); D009110 (Mumps Vaccine) - OMIM: Not applicable — mumps is an acquired infectious disease, not a Mendelian disorder, so it has no OMIM phenotype/gene entry. - Orphanet: Not applicable/not listed — Orphanet is scoped to rare diseases, and mumps is a common (historically near-universal) childhood infection, so it falls outside Orphanet's curation scope. - MONDO: A MONDO term for mumps should exist (mumps is xref'd from ICD-11/MeSH-derived disease ontologies); the exact MONDO CURIE should be confirmed with OAK (runoak -i sqlite:obo:mondo search "mumps") before use in a dismech entry rather than asserted here, consistent with this project's anti-hallucination policy. - NCBITaxon (pathogen): NCBITaxon:1979165 Orthorubulavirus parotitidis (mumps virus); older taxonomy/PMID literature uses Mumps orthorubulavirus / Mumps rubulavirus.

Synonyms: Epidemic parotitis; infectious parotitis; parotitis epidemica.

Evidence basis for this report: The information below is derived from aggregated disease-level resources — clinical/epidemiological reviews, CDC/ECDC/WHO surveillance guidance, and primary virology/immunology literature — rather than from any single patient-level EHR dataset. Frequencies given for complications (orchitis, meningitis, etc.) are pooled population-level estimates from outbreak surveillance and systematic review, not individual case data.

2. Etiology

Causal agent. Mumps is caused exclusively by mumps virus (MuV), a non-segmented, negative-sense single-stranded RNA virus. It is monotypic (a single serotype) but genetically diverse, currently classified into 12 recognized genotypes (A–N, excluding some letters) based on sequence variation in the small hydrophobic (SH) and hemagglutinin-neuraminidase (HN) genes, the two most variable regions of the genome (PMC4268314; microbewiki). There is no genetic (Mendelian) causal component — this is a purely infectious etiology.

Risk factors: - Vaccination status — the dominant risk factor. Unvaccinated individuals and those who never received MMR have the highest attack rates; however, modern outbreaks are increasingly driven by waning vaccine-induced immunity in adults who received both childhood doses years earlier. A meta-analysis found single-dose vaccinees had a 35.7% outbreak attack rate versus 16.4% for two doses and 10.1% for three doses (PMC12711706), and secondary vaccine failure (loss of protection after initially adequate response) is estimated at roughly 5% of recipients 6–26 years post-vaccination. - Age — adults show the highest attack rates in contemporary outbreaks (31.8% pooled, versus 13.6% in children 0–10 years) (PMC12711706), a reversal of the pre-vaccine-era pattern where school-age children (5–9 years) bore the highest burden. - Congregate/close-contact settings — university dormitories, military barracks, and other high-density-contact environments are classic outbreak amplifiers (e.g., the 2006 Iowa outbreak, the 2024–2025 Canadian outbreak with 5,078 cases as of October 2025). - Genotype mismatch — outbreaks in vaccinated populations are disproportionately caused by genotype G viruses, phylogenetically distant from the genotype A Jeryl Lynn vaccine strain that has not circulated naturally since the 1980s; neutralizing antibody titers against genotype G are roughly half those against the homologous vaccine strain, though still generally protective (PMC/FDA science forum data; PMC9044963). - Season — winter/spring peaks in temperate climates in the pre-vaccine era; less pronounced seasonality now. - Sex — no strong sex-based susceptibility difference for infection itself, though male sex is a strong risk modifier for a specific complication (orchitis, post-pubertal only).

Protective factors: - Two-dose MMR vaccination — approximately 97% protective; single dose approximately 78–88% (varies by study/era). - Prior natural infection — confers durable, generally lifelong immunity (reinfection is rare though case reports exist). - Passive maternal antibody — protects infants for the first several months of life. - No specific host genetic protective variant has been characterized in the literature; unlike many chronic/genetic disorders, host genomic susceptibility loci for mumps (e.g., HLA associations) have not been robustly established in the literature surveyed — this remains a relative knowledge gap rather than a demonstrated null finding.

Gene-environment interactions: Not applicable in the classic sense (no known host genetic susceptibility locus to interact with viral exposure); the principal "gene x environment"-analogous axis in mumps is viral genotype × vaccine-induced immune repertoire (i.e., genotype G circulating strains vs. genotype A vaccine-elicited antibody repertoire), which functions as the closest analog to a modifier-gene interaction in this disease.

3. Phenotypes

Mumps phenotypes span symptoms/signs of the primary parotitis syndrome and several organ-specific complications from hematogenous viral dissemination. Frequencies below are pooled from a 2025 systematic review/meta-analysis of 47 studies/71,174 cases spanning 2004–2024 (PMC12711706) and CDC/ECDC clinical sources; note these are population/outbreak-level frequencies, not always internally consistent across sources (older sources give higher figures for orchitis/meningitis than the most recent meta-analysis, reflecting improved case ascertainment and vaccination status of study populations).

*HP terms marked "verify" should be confirmed against the canonical label via OAK (runoak -i sqlite:obo:hp info <ID> -O obo) before use, per this project's anti-hallucination policy — several are given from memory and their exact identifiers/labels were not independently re-verified against the ontology in this research pass.

Quality of life impact: The acute illness is typically self-limited with full recovery over 1–2 weeks; the QoL-significant long-term sequelae are (1) permanent unilateral SNHL, which can affect language development if occurring in early childhood and sound localization/social function generally, and (2) testicular atrophy following severe/bilateral orchitis, which is a recognized but not well-quantified contributor to (usually not complete) subfertility. Encephalitis survivors may have residual neurologic deficits. No dedicated mumps-specific QoL instrument was identified in this search; general EQ-5D/SF-36 data specific to mumps sequelae were not found.

4. Genetic/Molecular Information

Mumps is not a genetic disease in the host-Mendelian sense (no OMIM phenotype, no ClinVar variant classification, no host causal gene) — the "genetic/molecular" content relevant to a dismech entry is entirely on the viral side:

• Viral genome: Non-segmented, negative-sense ssRNA genome of 15,384 nucleotides, encoding seven genes in the order 3′-N-V/P/I-M-F-SH-HN-L-5′ (nucleoprotein, V/phospho-/I proteins, matrix, fusion, small hydrophobic, hemagglutinin-neuraminidase, large/polymerase) (PMC4268314).
• Key viral proteins and function:
• HN (hemagglutinin-neuraminidase): Mediates receptor binding (attachment) to sialylated glycan receptors on host cells and has neuraminidase activity for viral release; a major target of neutralizing antibodies and the protein most implicated in genotype-specific antigenic differences (PMC6127219; PMC2933592).
• F (fusion) protein: Mediates fusion of viral and host membranes following HN-triggered conformational change, enabling nucleocapsid entry (PMC8471308).
• SH protein: A 57-amino-acid type I membrane protein; the single most variable genomic region (basis of genotyping A–N) and implicated in modulating host innate immune antagonism/apoptosis, though dispensable for viral growth in culture (Journal of Virology jvi.02686-10; PMC1367141).
• Variations in HN and SH amino acid sequence have been statistically associated with neurovirulence (differential propensity to cause CNS complications), based on comparison of mumps cases with vs. without neurologic symptoms (PMC3634820).
• Genotypes: 12 recognized genotypes (A–N minus a few unused letters) based on SH/HN sequence. Genotype A is the Jeryl Lynn/RIT 4385 vaccine lineage (no longer in natural circulation since the 1980s); genotype G is the genotype responsible for the majority of contemporary outbreaks in vaccinated populations in the US/UK/Netherlands, and is antigenically distinct enough from genotype A to have driven development of genotype-G-matched candidate vaccines (FDA Science Forum; PMC9044963; jvi.01983-21).
• Host genetics: No robustly replicated human susceptibility locus (HLA or otherwise) for mumps infection or complication severity was identified in this literature search — this appears to be a genuine gap rather than a well-characterized null result, and is analogous to the "no established host genetic risk factor" situation seen for many acute self-limited viral infections that have not been subjected to large-scale host GWAS.
• Somatic vs. germline: Not applicable (infectious, not neoplastic/genetic).
• Epigenetics: No disease-specific host epigenetic mechanism has been characterized in the literature reviewed.
• Chromosomal abnormalities: Not applicable.

5. Environmental Information

• Environmental/toxin factors: None — mumps is a purely infectious disease with no toxin, pollutant, or occupational-exposure contribution.
• Lifestyle factors: Close-contact behaviors (shared drinks/utensils, kissing, crowded living — dormitories, military barracks) are the principal "lifestyle" risk modifiers, since transmission is via respiratory droplets/direct saliva contact and requires prolonged close contact.
• Infectious agent: Mumps virus (MuV), genus Orthorubulavirus, family Paramyxoviridae. NCBI Taxonomy entry should be confirmed (NCBITaxon search for "Mumps orthorubulavirus"/"Orthorubulavirus parotitidis"). Enveloped, pleomorphic, ~200 nm virion.
• Transmission: Person-to-person via respiratory droplets or direct contact with saliva/fomites; virus is shed in saliva from approximately 1 week before to 1 week after parotitis onset (CDC/PMC4268314), with the practically infectious window commonly cited as 2 days before to 5 days after parotitis onset. Asymptomatic shedders can transmit virus.

6. Mechanism / Pathophysiology

Causal chain — initial trigger to clinical manifestation:

1. Respiratory entry and local replication: MuV is inhaled/contacted via respiratory droplets or saliva and initially infects and replicates in epithelial cells of the upper respiratory tract (nasopharynx) and regional (cervical) lymph nodes (PMC8471308).
2. Viral entry mechanism: MuV attaches via its HN glycoprotein to host-cell sialylated glycan receptors — a trisaccharide containing α2,3-linked sialic acid in unbranched chains (e.g., 3′-sialyllactosamine), with additional recognition of sialyl-Lewis X and GM2 ganglioside as receptors (PMC5068328/PMID:27671656; PMC6639266/PMID:31118251). HN binding triggers conformational changes propagated to the F protein, driving membrane fusion and nucleocapsid entry (PMC8471308). Beyond sialic-acid-mediated attachment, the receptor tyrosine kinases AXL and MER facilitate productive infection by suppressing cellular innate antiviral responses in target cells such as Sertoli/Leydig cells (PMC7336603).
3. Primary viremia and systemic dissemination: After several replication cycles in the respiratory tract/lymph nodes, the virus enters the bloodstream (viremia) during the early acute phase and disseminates to distant organs with permissive glandular and neural tropism — principally the salivary glands (parotid > submandibular/sublingual), but also testes/ovaries, pancreas, thyroid, and the central nervous system (meninges/brain/inner ear) (PMC4268314; PMC8471308).
4. Organ-specific inflammatory injury:
5. Salivary gland (parotitis): Viral replication in ductal/acinar epithelium triggers local inflammatory cell infiltration, glandular edema, and interstitial inflammation, producing the classic painful parotid swelling.
6. Testis (orchitis)/ovary (oophoritis): Direct viral infection of Sertoli and Leydig cells (testis) or granulosa cells (ovary) triggers a robust local innate immune response — Toll-like receptor 2 (TLR2) and RIG-I (retinoic-acid-inducible gene I) pathway activation — producing TNF-α, IL-6, MCP-1, CXCL10, and type I interferons (IFN-α/β) (Sci Rep srep19507; PMC4725973; ScienceDirect S0303720716302738). The resulting local inflammatory swelling within the non-distensible tunica albuginea (testis) can cause ischemic injury contributing to later testicular atrophy.
7. CNS (meningitis/encephalitis): Virus reaches the meninges/CNS hematogenously (and possibly via infected leukocytes), producing a lymphocytic (aseptic) meningitis; true encephalitis (parenchymal invasion) is rarer and is the principal cause of mumps mortality.
8. Inner ear (sensorineural hearing loss): Proposed mechanism is hematogenous viral endolymphatic labyrinthitis — direct viral invasion of the cochlea via the bloodstream (rather than tympanogenic or meningogenic spread) — producing atrophy/destruction of cochlear hair cells and consequent sudden, usually unilateral, profound and permanent SNHL (PMID:3767776; PMID:13762395).
9. Pancreas (pancreatitis): Direct viral invasion of pancreatic tissue is proposed, generally producing transient exocrine/endocrine dysfunction (hyperglycemia); rare reports of subsequent (type 3c/pancreatogenic) diabetes remain of uncertain causality.
10. Adaptive immune control and resolution: Mumps-specific CD4+ T cells (IFN-γ-producing) and CD8+ cytotoxic T cells (granzyme A/B, perforin) are induced; T-cell response rates are notably robust in natural infection (~80% positive) versus vaccination (~70%), and a 2021 study found that natural infection but not vaccination elicits certain cytotoxic-T-cell epitope responses, offering one candidate explanation (beyond antibody waning/genotype mismatch) for vaccine-breakthrough susceptibility (PMC/PMID:34211021).

Upstream vs. downstream: Respiratory entry → regional lymphatic replication → viremia are upstream/shared steps common to all downstream organ-specific complications, which are essentially independent, parallel branches (parotitis, orchitis/oophoritis, meningoencephalitis, labyrinthitis, pancreatitis) triggered by tissue-specific viral tropism plus locally-mounted innate/inflammatory responses, rather than a single linear cascade.

Suggested GO terms: GO:0046718 (viral entry into host cell), GO:0019064 (fusion of virus membrane with host plasma membrane), GO:0033130 (sialic acid binding — verify), GO:0045087 (innate immune response), GO:0060337 (type I interferon signaling pathway), GO:0006954 (inflammatory response), GO:0002250 (adaptive immune response).

Suggested CL terms: CL:0000216 (Sertoli cell), CL:0000178 (Leydig cell), CL:0000501 (granulosa cell), auditory/cochlear hair cell (verify exact CL ID), salivary gland acinar/ductal epithelial cell (verify exact CL ID), CL:0000624 (CD4+ T cell), CL:0000625 (CD8+ T cell).

Molecular profiling / advanced technologies: No transcriptomic (GEO), proteomic (PRIDE), metabolomic, single-cell, or spatial-transcriptomic dataset specific to human mumps infection was identified in this search — this is a data gap; most mechanistic work on mumps innate immune signaling has used mouse Sertoli/Leydig/granulosa cell culture models rather than -omics profiling of human tissue.

7. Anatomical Structures Affected

Organ level: - Primary: Salivary glands — parotid gland (most common; UBERON:0001830), submandibular gland (UBERON:0001736), sublingual gland. - Secondary (complication-associated): Testis (UBERON:0000473) and epididymis; ovary (UBERON:0000992); pancreas (UBERON:0001264); meninges (UBERON:0002360) and brain parenchyma (UBERON:0000955); inner ear/cochlea (UBERON:0001844); breast (mastitis); heart (rare myocarditis); kidney (rare nephritis); thyroid (rare thyroiditis, case reports). - Body systems involved: Exocrine/glandular system (primary), reproductive system, digestive/endocrine system (pancreas), nervous system (CNS and inner ear/CN VIII), and (rarely) cardiovascular and renal systems.

Tissue/cell level: Glandular epithelium (ductal and acinar cells of salivary glands), Sertoli and Leydig cells of testis, granulosa cells of ovary, cochlear hair cells (mechanotransducing sensory epithelium), pancreatic acinar/islet tissue, meningeal and neuronal/glial tissue.

Subcellular level: No disease-defining subcellular/organelle pathology has been characterized beyond generic viral-replication cytopathic changes; relevant GO Cellular Component terms would be plasma membrane (site of HN/F-mediated entry) and endoplasmic reticulum/Golgi (viral glycoprotein processing) rather than a disease-specific organelle lesion.

Localization/laterality: Parotitis is bilateral in roughly 70–90% of cases in most series (unilateral in the remainder); orchitis is unilateral in 60–83% of affected males; sensorineural hearing loss is characteristically unilateral (bilateral mumps deafness is very uncommon).

8. Temporal Development

• Onset: Incubation period 12–25 days (average commonly cited as 16–18 days; some sources state 2–4 weeks) following exposure (CDC clinical overview; PMC4268314). Onset is typically preceded by a 1–2 day nonspecific prodrome (fever, headache, myalgia, malaise, anorexia) before glandular swelling appears.
• Onset pattern: Acute.
• Progression/stages: Prodrome → parotid (± other salivary gland) swelling peaking over 1–3 days → gradual resolution over about 1 week. Organ-specific complications (orchitis, meningitis, pancreatitis) typically follow parotitis onset by days (orchitis classically 4–8 days later) but can occasionally precede parotitis or occur in its absence.
• Rate/course: Rapid onset, generally self-limited acute illness; no chronic/relapsing form of mumps itself exists (unlike the chronic sequelae it can leave behind — SNHL, testicular atrophy).
• Duration: Self-limited — acute illness resolves within 1–2 weeks in the vast majority of cases; sequelae (deafness, testicular atrophy) are permanent when they occur, but the causal infection itself does not become chronic.
• Remission: Not applicable in the relapsing-disease sense; the infection resolves with adaptive immunity, generally rendering the person subsequently immune (natural infection immunity considered lifelong, though not absolute).
• Critical periods: The pubertal/post-pubertal period is the critical window of vulnerability for orchitis/oophoritis (rare before puberty); first-trimester pregnancy has been proposed (weak, largely historical evidence) as a window of increased miscarriage risk, though modern controlled data do not clearly support increased congenital malformation risk (GOV.UK mumps-in-pregnancy guidance; PMC3296145).

9. Inheritance and Population

Epidemiology: - Pre-vaccine era: Incidence of 100–1,000 per 100,000 population per year globally, with epidemics recurring every 2–5 years, peaking in winter/spring in temperate climates; in the US, >185,000 cases/year were reported before vaccine introduction, predominantly in children aged 5–9 years. - Contemporary WHO surveillance: ~500,000 cases/year reported to WHO on average 1999–2019 (likely a substantial undercount, since mumps is not notifiable in many countries). - Vaccine impact: One-dose schedules reduce incidence by >88%; two-dose schedules by ~97%. - Recent outbreaks: A large ongoing Canadian outbreak beginning October 2024 reached 5,078 cases by mid-October 2025; a 2023–2024 outbreak in Shivamogga, India provided an economic case for MMR inclusion in that country's universal immunization program; recurrent outbreaks have also affected US universities/military populations and parts of Europe. - Pooled outbreak attack rate (2004–2024 meta-analysis, 47 studies/21 countries/71,174 cases): 14.5% overall; regional variation from ~7.6% (Europe) to ~29.2% (Americas)/28.8% (Eastern Mediterranean).

Inheritance pattern: Not applicable — mumps is an acquired infection, not a heritable genetic disease; there is no Mendelian inheritance pattern, penetrance, expressivity, anticipation, germline mosaicism, founder effect, consanguinity role, or carrier frequency to report. (These fields, standard for genetic disorders in this template, simply do not apply to an infectious-disease dismech entry.)

Population demographics: - Age distribution: Historically concentrated in school-age children (5–9 years); in the contemporary vaccine era, disproportionately shifted toward young adults (college-age and older), reflecting waning immunity plus dense-contact settings. - Sex ratio: Roughly equal susceptibility to infection between sexes; complication type is markedly sex-specific (orchitis only in post-pubertal males; oophoritis/mastitis only in post-pubertal females). - Geographic distribution: Global; higher contemporary attack rates reported in the Americas and Eastern Mediterranean regions versus Europe and South-East Asia in the recent meta-analysis, likely reflecting differences in vaccination coverage/schedule (2 vs. 3 dose) and case-ascertainment practices rather than intrinsic regional biology. - Genotype geography: Genotype G circulates widely in outbreak settings in North America/Europe; other genotypes (e.g., genotype C, D, H, J, K) show more regionally restricted circulation historically (e.g., parts of Asia).

10. Diagnostics

Preferred specimen/method: A buccal swab specimen, collected after massaging the parotid gland area for ~30 seconds, obtained ≤3 days after parotitis onset, tested by real-time RT-PCR (rRT-PCR) — this is the CDC-preferred combination for laboratory confirmation (CDC Mumps Laboratory Testing/Specimen Collection guidance, Jan 2025 update).

Serology (IgM): - If specimen collection occurs >3 days after onset, CDC recommends collecting both a buccal swab for rRT-PCR and a serum specimen for IgM. - IgM capture ELISA detects only 46–71% of rRT-PCR-confirmed cases — sensitivity is inversely related to vaccination status: highest detection in unvaccinated persons, intermediate after one dose, lowest after two doses — a well-documented pitfall in outbreaks among highly vaccinated populations (PMC5299122). - A positive IgM result is supportive but not confirmatory evidence per the CSTE case definition.

Genotyping: SH-gene sequencing from RT-PCR-positive specimens is used for genotype assignment (surveillance/outbreak-source tracing), not for individual patient diagnosis.

Imaging: Not typically required for diagnosis; ultrasound may be used to characterize orchitis/oophoritis or distinguish parotitis from other causes of parotid swelling (sialolithiasis, bacterial parotitis, tumor) in atypical presentations.

Differential diagnosis: Bacterial (suppurative) parotitis, parotid duct stone/sialadenitis of other cause, HIV-associated parotid enlargement, other viral parotitis (parainfluenza, influenza A, EBV, CMV, coxsackievirus, adenovirus), Sjögren's syndrome/juvenile recurrent parotitis (non-infectious sialadenitis), and — for isolated CNS presentations — other causes of aseptic meningitis/encephalitis (enterovirus is the most common overall cause).

Screening: No population screening program exists (mumps is prevented, not screened for); the relevant "screening" surrogate is serologic immunity screening (e.g., pre-employment healthcare-worker immunity checks) rather than disease screening.

11. Outcome/Prognosis

• Mortality: Case-fatality ratio estimated at 1.6–3.8 per 10,000 cases (PMC4268314), with essentially all deaths occurring in the context of encephalitis. Mortality is very low in the modern/vaccine era in high-resource settings.
• Morbidity/functional outcomes: The dominant long-term morbidity burdens are permanent unilateral sensorineural hearing loss (historically the leading cause of unilateral acquired childhood SNHL) and testicular atrophy after severe orchitis (contributing to, though rarely causing complete, subfertility — bilateral severe orchitis with bilateral atrophy causing infertility is described but uncommon). Encephalitis survivors can have residual neurologic deficits, though most mumps meningitis is self-limited without sequelae.
• Recovery: The acute systemic illness resolves fully in the great majority of patients within 1–2 weeks without any long-term consequence; complications, when they occur, are the exception rather than the rule (overall pooled outbreak complication rate ~10.3%, dominated by orchitis).
• Prognostic factors: Post-pubertal male sex (orchitis risk), unvaccinated/single-dose status (higher complication rates), and encephalitis occurrence (the dominant mortality predictor).
• Prognostic biomarkers: None specific/validated beyond general clinical/CNS-involvement assessment.

12. Treatment

Mumps has no specific antiviral therapy — management is entirely supportive.

Pharmacotherapy (supportive): - Antipyretics/analgesics (e.g., acetaminophen, NSAIDs) for fever, headache, and glandular/testicular pain. - Scrotal support and analgesia (including, in severe orchitis, sometimes corticosteroids, though evidence for corticosteroid benefit in mumps orchitis is limited/not robust). - No antiviral drug (e.g., ribavirin) has demonstrated proven clinical benefit and none is a standard-of-care recommendation; ribavirin (CHEBI:63580) has been studied experimentally in vitro/in some case reports but is not an established treatment.

Advanced therapeutics: Not applicable — no gene therapy, cell therapy, RNA-based therapy, targeted therapy, or immunotherapy is used for mumps itself (these modalities are not relevant to this acute self-limited viral infection).

Surgical/interventional: Not routinely required; rare surgical intervention (e.g., testicular decompression) has been described anecdotally for severe orchitis but is not standard practice.

Supportive/rehabilitative care: Bed rest, hydration, dietary modification for pancreatitis (limiting oral intake if pancreatitis is significant), and — for complication sequelae — audiology/hearing rehabilitation (hearing aids/cochlear implant evaluation) for permanent SNHL.

Isolation/infection control: Isolation of infected individuals for 5 days after parotitis onset (droplet precautions) is a key "treatment-adjacent" public-health action to limit transmission (CDC).

Suggested MAXO terms: MAXO:0000950 (supportive care); MAXO:0001017 (vaccination — for the preventive, not therapeutic, arm); a hearing-rehabilitation/audiology-intervention MAXO or NCIT term for post-SNHL management (verify specific ID).

Experimental treatments: No active mumps-specific therapeutic (as opposed to vaccine) clinical trials were identified; most current mumps-related ClinicalTrials.gov activity concerns vaccine strategies (e.g., third-dose MMR effectiveness studies), not treatment of acute disease.

13. Prevention

Primary prevention — vaccination: The mainstay of mumps prevention is the live-attenuated mumps component of the MMR (or MMRV) vaccine, most commonly the Jeryl Lynn strain (genotype A) in the US (e.g., M-M-R II; PMC8903938 — "40 years of global experience with M-M-RII"), or the RIT 4385/Urabe/Leningrad-Zagreb strains used in other countries. Standard US schedule: first dose at 12–15 months, second dose at 4–6 years, achieving ~97% two-dose effectiveness. A third MMR dose has been used/modeled as an outbreak-control measure in settings of ongoing transmission (e.g., University of Iowa outbreak modeling; PMID:39401354), and a 2025 individual-based stochastic modeling study evaluated optimized mumps-vaccination strategies (Lancet eClinicalMedicine, 2025).

Secondary prevention: Prompt case identification (RT-PCR/IgM per CDC algorithm above) and isolation of cases (5 days post-parotitis-onset) to interrupt outbreak chains; outbreak-response vaccination (e.g., targeted third-dose campaigns in affected cohorts).

Tertiary prevention: Management of complications to limit their sequelae — e.g., prompt recognition/supportive management of orchitis to reduce (though not eliminate) risk of testicular atrophy; audiologic monitoring/early hearing rehabilitation after mumps-associated SNHL.

Genetic/prenatal screening, carrier screening: Not applicable (non-genetic, infectious disease).

Public health interventions: Case-based and outbreak surveillance (nationally notifiable in the US and most high-income countries), outbreak investigation and targeted vaccination campaigns in affected institutions (universities, correctional facilities, military units), health education about transmission via saliva/respiratory droplets.

Prophylaxis: Post-exposure vaccination is not established as effective for preventing disease in an already-exposed contact (unlike, e.g., measles), since the incubation period generally exceeds the time needed to mount vaccine-induced protection; there is no approved mumps-specific immunoglobulin prophylaxis in routine use.

14. Other Species / Natural Disease

Mumps virus is essentially human-restricted in its natural epidemiology — there is no significant naturally occurring reservoir or endemic disease of mumps virus in non-human species; unlike many zoonotic paramyxoviruses, mumps has no recognized zoonotic cycle or wildlife/companion-animal reservoir in the literature reviewed. This is itself a notable feature worth flagging in a dismech entry (i.e., "naturally occurring disease in other species" = essentially none, in contrast to the extensive experimental/model-organism literature below). No OMIA (Online Mendelian Inheritance in Animals) entries or veterinary clinical disease reports of natural mumps virus infection were identified.

15. Model Organisms

Mumps virus pathogenesis has been studied across several experimental animal systems, with rhesus macaques established as the best available model:

• Rhesus macaque (NCBITaxon:9544): The single best-characterized model — intranasal and intratracheal inoculation with clinical MuV isolates (e.g., MuV-IA, the 2006 Iowa outbreak strain) produces classic clinical mumps signs 2–4 weeks post-infection, and macaques were extensively used in the early 1990s for parotid-gland and CNS pathogenesis studies (PMC3700206/PMID:23678169; Tandfonline 10.1080/21645515.2016.1210745). Rhesus macaques were the most susceptible species tested to clinical MuV-IA infection.
• Mice: Generate humoral and cellular immune responses to MuV-IA infection but show no overt clinical illness; used mainly for immunogenicity/vaccine-candidate evaluation (e.g., Jeryl-Lynn-immunized mice challenged with genotype G vaccine candidates, PMC9044963) and for innate-immune mechanistic studies in isolated Sertoli/Leydig/granulosa cell culture (Sci Rep srep19507).
• Ferrets: Similarly generate immune responses without overt clinical disease upon MuV-IA infection; used as an intermediate model in comparative pathogenesis studies (PMC3700206).
• Cotton rat (Sigmodon hispidus): Recently used to evaluate immunogenicity of mumps vaccine candidate strains (ScienceDirect S0264410X25009375, 2025).
• Newborn hamsters/neonatal mice (intracerebral/intraperitoneal inoculation): Historical models confirming neurotropism of MuV to neurons, with differing neurovirulence between viral strains — used to map the SH/HN neurovirulence determinants discussed in Section 6.
• Other historically examined species: Cat, guinea pig, marmoset — generally limited replication and are not standard models today.

Limitations: MuV replication is limited in rodents generally, restricting their utility for humoral/cellular immunogenicity studies (though useful for innate-response mechanism and vaccine-candidate screening); no small-animal model faithfully recapitulates the full clinical parotitis/orchitis/meningoencephalitis/SNHL phenotype spectrum seen in humans — only rhesus macaques approximate the clinical disease, which limits throughput and scale for pathogenesis studies given cost/ethical constraints of NHP work. In dismech terms, this would represent good material for a HUMAN_MODEL_MISMATCH-style discussion node if a mechanistic claim (e.g., a specific SH-mediated neurovirulence mechanism) is sourced primarily from rodent/cell-culture data without confirmed human-tissue correlation.

Cell-culture/in vitro systems: Mouse Sertoli cell (TM4), Leydig cell, and ovarian granulosa cell lines have been used extensively to dissect the TLR2/RIG-I-mediated innate cytokine response to MuV infection described in Section 6 (Sci Rep srep19507; PMC4725973; ScienceDirect S0303720716302738); these are IN_VITRO/MODEL_ORGANISM-adjacent (mouse-derived cell lines) evidence sources per this project's evidence-source classification convention, and should not be used as the sole support for human phenotype claims without corroborating human clinical evidence.

Summary of Suggested Ontology Terms for KB Curation

Key Gaps Flagged for Curators

1. No confirmed MONDO/Orphanet ID was located in this search — needs OAK/manual lookup before entry creation.
2. Host genetic susceptibility (HLA or other loci) is essentially uncharacterized in the literature — worth an explicit KNOWLEDGE_GAP discussion node rather than assuming absence of any genetic modifier.
3. Mumps-in-pregnancy risk evidence is thin and largely historical (a single 1966 study); modern data do not support a clear congenital-malformation signal — an appropriate candidate for a KNOWLEDGE_GAP/nuanced-evidence framing rather than a firm causal claim.
4. Pancreatitis→diabetes causality is explicitly stated as unclear in the reviewed literature — do not assert a firm causal pathway.
5. Direct human tissue/-omics data (transcriptomic, proteomic) for mumps pathogenesis is essentially absent; most cellular-mechanism evidence is mouse-cell-line-derived, a good HUMAN_MODEL_MISMATCH candidate if a specific innate-immune mechanistic claim is imported into a pathophysiology node.

Sources: - Molecular biology, pathogenesis and pathology of mumps virus - PMC - Function of Small Hydrophobic Proteins of Paramyxovirus - PMC - Discrimination of Mumps Virus Small Hydrophobic Gene Deletion Effects — J Virol - Differences in antigenic sites... genotype A and G mumps virus surface proteins - PMC - A 176 amino acid polypeptide derived from the mumps virus HN ectodomain - PMC - Genetic Variation in the HN and SH Genes of Mumps Viruses - PMC - Unique Tropism and Entry Mechanism of Mumps Virus - PMC - Roles of Sialic Acid, AXL, and MER RTKs in Mumps Virus Infection - PMC - Trisaccharide containing α2,3-linked sialic acid is a receptor for mumps virus - PNAS/PMC - Molecular Mechanism of the Flexible Glycan Receptor Recognition by Mumps Virus - PMC - Mumps Complications and Effects of Mumps Vaccination, England and Wales, 2002–2006 - PMC - Clinical Features of Mumps | CDC - Clinical Overview of Mumps | CDC - Chapter 15: Mumps | Pink Book | CDC - Epidemiological trends and determinants of mumps outbreaks: a systematic review and meta-analysis - PMC - Modeling the population-level impact of a third dose of MMR vaccine - PubMed - Mumps Outbreak in Shivamogga, India (2023–2024) - PMC - Evaluation and optimization of mumps-containing vaccination strategies - eClinicalMedicine - Deafness following mumps: the possible pathogenesis and incidence of deafness - PubMed - Inner ear pathology in deafness due to mumps - PubMed - The potential dysfunction of otolith organs in patients after mumps infection - PMC - Mumps Infection With Parotitis, Pancreatitis, and Orchitis - PMC - Mumps virus-induced innate immune responses in mouse Sertoli and Leydig cells - Sci Rep - Immune Responses to Mumps Vaccine in Adults Vaccinated in Childhood - PMC - Mumps virus induces innate immune responses in mouse ovarian granulosa cells - ScienceDirect - Novel mumps virus epitopes reveal robust cytotoxic T cell responses - Sci Rep - Antibody Induced by Immunization with the Jeryl Lynn Mumps Vaccine Strain - PubMed - A Mumps Virus Genotype G Vaccine Candidate — FDA Science Forum - Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice - PMC - Exploring the Mumps Virus Glycoproteins: A Review - PMC - Immunogenicity of mumps virus vaccine candidates matching circulating genotypes - PubMed - MMRV Testing for Clinicians (Jan 2025) | CDC - Serology to Diagnose Mumps | CDC - Challenges in Interpretation of Diagnostic Test Results in a Mumps Outbreak - PMC - Mumps Clinical Testing | CDC - Mumps Specimen Collection | CDC - Infection of Mice, Ferrets, and Rhesus Macaques with a Clinical Mumps Virus Isolate - PMC - Establishing a small animal model for evaluating protective immunity against mumps virus - PLOS ONE - Evaluation of immunogenicity of mumps vaccine strains in cotton rat model - ScienceDirect - Mumps virus pathogenesis: Insights and knowledge gaps - Taylor & Francis - Presumed Cases of Mumps in Pregnancy: Clinical and Infection Control Implications - PMC - Mumps: risk in pregnancy, infection in healthcare settings and MMR vaccine - GOV.UK - Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII - PMC - Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity - PMC - Chapter 9: Mumps | Manual for the Surveillance of Vaccine-Preventable Diseases | CDC - 1D80 Mumps - ICD-11 MMS